The Hidden Value of Nordic Life Science Innovation
By Olesia Karvetskaia, Business Development Manager
June 15, 2026
Many Nordic life science companies undervalue themselves—not due to weak science, but because their narrative is unclear.
In this interview, Altar Munis outlines what UK investors actually focus on when evaluating Nordic companies. His perspective challenges the common assumption that geography is the main barrier, suggesting instead that a compelling, well-structured story plays a far more decisive role than most expect.
The conversation was recorded as part of Venture Road UK, an initiative by Ventures Accelerated Life Science and Phosworks bringing together founders, investors, scientists, and ecosystem leaders from the Nordics and the UK around the future of precision health and life sciences.
Altar Munis, Biotech Investor | R&D and Innovation Strategy